ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

GM Honors Blackburn, Kuhl, Phelps, Speizer, And Willett

June 8, 2001

Virus Working Group Suggests 14 Projects As Suitable For New Contract Proposals

March 1, 1974

R. Lee Clark, 87, M.D. Anderson Mastermind, dies

May 13, 1994

Cholesterol-Lowering Drugs May Prevent Breast Cancer

October 31, 2003

PBS Runs Misleading Lung Screening Claim; Reporter and Subject on Mount Sinai Faculty

October 11, 2013